Mounjaro vs Zepbound: Same Drug, Different Brands — Why the Distinction Matters for Coverage and Cost

Mounjaro and Zepbound are the same active ingredient (tirzepatide), at the same weekly doses (2.5–15 mg), made by the same manufacturer (Eli Lilly), with the same injection schedule, the same titration table, the same boxed warning, and the same mechanism of action. The FDA issued two separate brand approvals because the agency approves drugs by indication, not by molecule: Mounjaro is the type 2 diabetes brand (approved May 13, 2022); Zepbound is the chronic weight management brand (approved November 8, 2023). That distinction, invisible at the molecular level, creates real-world coverage and cost differences that affect millions of patients. This article explains exactly why both names exist, what each one's label says verbatim, how insurance treats them differently, and what it means if you are prescribed one brand for a use the other brand was specifically built for.

TL;DR — same drug, different brands

If you have five minutes, here is every material fact:

The bottom line: if you are a patient wondering whether these are the same medication, the biochemical answer is yes. If you are asking whether your insurance will treat them the same, the administrative answer is no.

The active ingredient: tirzepatide is identical in both

Section 11 (Description) of both DailyMed labels uses nearly identical chemical language because the molecule is chemically identical. The Mounjaro label (SetID d2d7da5d-ad07-4228-955f-cf7e355c8cc0) states verbatim:

“MOUNJARO (tirzepatide) injection, for subcutaneous use, contains tirzepatide, a once weekly GIP receptor and GLP-1 receptor agonist. Tirzepatide is based on the GIP sequence and contains aminoisobutyric acid (Aib) in positions 2 and 13, a C-terminal amide, and Lys residue at position 20 that is attached to 1,20-eicosanedioic acid via a linker. The molecular weight is 4813.53 Da and the empirical formula is C 225H 348N 48O 68.”Mounjaro PI Section 11, DailyMed SetID d2d7da5d, revised 4/2026

The Zepbound label (SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b) states verbatim:

“ZEPBOUND (tirzepatide) injection, for subcutaneous use, contains tirzepatide, a GIP receptor and GLP-1 receptor agonist. Tirzepatide is based on the GIP sequence and contains aminoisobutyric acid (Aib) in positions 2 and 13, a C-terminal amide, and Lys residue at position 20 that is attached to 1,20-eicosanedioic acid via a linker. The molecular weight is 4813.53 Da and the empirical formula is C 225H 348N 48O 68.”Zepbound PI Section 11, DailyMed SetID 487cd7e7, revised 4/2026

The molecular weight (4813.53 Da), the empirical formula (C 225H 348N 48O 68), the peptide backbone structure, and the fatty-acid linker at Lys-20 are identical. Both labels describe the formulation excipients identically as well: sodium chloride (4.1 mg), sodium phosphate dibasic heptahydrate (0.7 mg), and water for injection, in a 0.5 mL single-dose volume per injection.

Tirzepatide is a dual agonist: it activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor simultaneously. This dual-receptor mechanism is what makes tirzepatide distinct from semaglutide (Wegovy, Ozempic), which activates only the GLP-1 receptor. The dual-receptor activation is present in both Mounjaro and Zepbound because both contain the same tirzepatide molecule.

Why two brand names? The FDA approval pathway

The FDA approves drug applications (NDAs) for specific indications, not for molecules. A manufacturer may submit separate NDAs for the same active ingredient if each NDA is accompanied by clinical trial data demonstrating safety and efficacy for a distinct indication. Eli Lilly pursued exactly this strategy with tirzepatide:

• NDA 215866 (Mounjaro) — approved May 13, 2022. Supported by the SURPASS clinical trial program, which studied tirzepatide in adults with type 2 diabetes. The FDA indication: type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control.
• NDA 217806 (Zepbound) — approved November 8, 2023. Supported by the SURMOUNT clinical trial program, which studied tirzepatide in adults with obesity (with or without type 2 diabetes). The FDA indication: chronic weight management in adults with initial BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² with at least one weight-related comorbid condition. The obstructive sleep apnea (OSA) indication was added in December 2024 following the SURMOUNT-OSA trial.

This dual-brand structure is not unusual. Semaglutide, the active ingredient in Ozempic, Wegovy, and Rybelsus, follows the same pattern: Ozempic (NDA 209637) and Rybelsus (NDA 213182) are approved for type 2 diabetes; Wegovy (NDA 215256) is approved for chronic weight management. Same molecule, different brands, different approvals.

The consequence for patients: once a drug has an FDA-approved indication for a specific use, prescribers may legally write that drug for off-label uses (any use not listed in that specific brand's Section 1). But insurance carriers are generally not obligated to reimburse off-label prescriptions, and most commercial policies, Medicare Part D plans, and Medicaid programs explicitly restrict coverage to the FDA-approved indication on file for each NDA.

Indications side by side: when each is on-label

Section 1 (Indications and Usage) of the Mounjaro label states verbatim:

“MOUNJARO is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.”Mounjaro PI Section 1, DailyMed SetID d2d7da5d, revised 4/2026

Section 1 of the Zepbound label states verbatim:

“ZEPBOUND is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. (1) to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. (1) Limitations of Use: Coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended.”Zepbound PI Section 1, DailyMed SetID 487cd7e7, revised 4/2026

Practical translation:

• Mounjaro is on-label when a patient has a confirmed diagnosis of type 2 diabetes mellitus and the prescriber is targeting glycemic control (HbA1c reduction). The label covers adults and pediatric patients 10 years and older.
• Zepbound is on-label when a patient has a confirmed BMI ≥ 30 kg/m² (obesity) or a BMI ≥ 27 kg/m² (overweight) with at least one qualifying weight-related comorbid condition (hypertension, dyslipidemia, obstructive sleep apnea, type 2 diabetes, or cardiovascular disease are typical examples in PA criteria). The OSA-specific pathway requires moderate-to-severe OSA (AHI ≥ 15/hour on polysomnography) in an adult patient with obesity.
• When a patient has both T2DM and obesity, the coverage decision is typically driven by the insurance carrier's prior authorization pathway. A patient with T2DM may qualify for Mounjaro under the diabetes PA criteria and for Zepbound under the obesity PA criteria — two different NDAs, two different coverage buckets, potentially on the same plan.

Notably, Mounjaro's indication does not exclude patients who also have obesity. Tirzepatide produces clinically significant weight loss in patients with T2DM, as demonstrated in the SURPASS trials. The label simply does not state weight loss as a primary indication — the primary outcome in SURPASS was HbA1c reduction, not weight loss.

Dosing is identical

Section 2.1 of the Mounjaro label states verbatim:

“The recommended starting dosage is 2.5 mg injected subcutaneously once weekly. After 4 weeks, increase to 5 mg injected subcutaneously once weekly. If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose. Maximum dosage: Adults: 15 mg subcutaneously once weekly. Pediatric patients 10 years of age and older: 10 mg subcutaneously once weekly.”Mounjaro PI Section 2.1, DailyMed SetID d2d7da5d, revised 4/2026

Section 2.1 of the Zepbound label states verbatim:

“The recommended starting dosage is 2.5 mg injected subcutaneously once weekly for 4 weeks. Increase the dosage in 2.5 mg increments after at least 4 weeks until recommended maintenance dosage is achieved. Consider treatment response and tolerability when selecting the maintenance dosage.”Zepbound PI Section 2.1, DailyMed SetID 487cd7e7, revised 4/2026

Both labels specify:

• Starting dose: 2.5 mg once weekly
• Escalation increment: 2.5 mg after at least 4 weeks at each step
• Maximum adult dose: 15 mg once weekly
• Route: subcutaneous injection in the abdomen, thigh, or upper arm
• Timing: any time of day, with or without meals

The implication for patients switching between brands: because the molecule, doses, and titration schedule are identical, a switch from Mounjaro to Zepbound (or the reverse) at the same dose strength is pharmacologically straightforward. The switch is an administrative event — a change in indication, a new prior authorization, and a new prescription — not a biological re-titration event. Prescribers generally maintain the current dose strength when switching brands unless they choose to adjust the dose independently. For the broader switching landscape across all GLP-1 medications, see our GLP-1 switching and dose equivalence guide.

Why insurance treats them differently

The insurance-coverage difference is the most consequential practical distinction between Mounjaro and Zepbound for the majority of patients. Here is the structural reason:

The indication tier problem

Commercial insurance plans assign drug coverage based on the FDA-approved indication tied to each NDA, not by active ingredient. Most commercial formularies have two distinct benefit buckets for tirzepatide:

• Diabetes / glucose-control tier: Mounjaro (NDA 215866) typically sits in this tier. Prior authorization criteria require a documented T2DM diagnosis, usually plus at least one prior antidiabetic medication (commonly metformin as a step therapy, with exceptions for renal contraindication or established CVD). A patient without T2DM cannot normally meet these criteria.
• Anti-obesity medication (AOM) / chronic weight management tier: Zepbound (NDA 217806) typically sits here. Prior authorization criteria require documented BMI meeting the threshold plus comorbidities, and often a documented period of behavioral modification (3–6 months in many plans). A patient without obesity meeting the threshold cannot normally meet these criteria.

These two tiers exist because Congress, and most employer-sponsored plan designs that followed it, historically treated diabetes as a medical necessity coverage category and obesity as an elective or lifestyle condition. The Treat and Reduce Obesity Act has been introduced repeatedly but not enacted as of 2026, so Medicare Part D exclusions on weight-loss drugs (except for cardiovascular risk reduction under Wegovy) remain in effect.

Medicare Part D coverage patterns

Medicare Part D covers Mounjaro when prescribed for T2DM because diabetes medications are a required benefit category. Medicare Part D does not cover Zepbound for chronic weight management because weight-loss drugs are excluded under 42 U.S.C. § 1395w-102(e)(2). The exception: Zepbound is covered under Part D when prescribed for obstructive sleep apnea, because the OSA indication is not classified as weight loss (it was approved for a diagnosable clinical condition). This OSA coverage pathway has opened a meaningful access route for patients on Medicare who have both obesity and moderate-to-severe obstructive sleep apnea.

Medicaid coverage patterns

Medicaid coverage is highly state-specific. Almost all state Medicaid programs cover Mounjaro (or tirzepatide generically) for T2DM because antidiabetic medications are a required benefit. Coverage of Zepbound for chronic weight management varies widely: some states cover it with PA criteria; many states exclude AOM entirely except for FDA-label carve-outs such as Zepbound for OSA or Wegovy for cardiovascular risk reduction. For the state-by-state Medicaid picture, see our GLP-1 insurance coverage: Medicare, Medicaid, and commercial guide.

Prior authorization criteria: the concrete difference

To make the distinction concrete, commercial insurer PA criteria for Mounjaro (tirzepatide NDA 215866) typically require:

• Confirmed diagnosis of type 2 diabetes mellitus (ICD-10 E11.x)
• HbA1c above the plan threshold (commonly HbA1c ≥ 7.5% or ≥ 8%)
• Prior or concurrent metformin trial (with exceptions for eGFR < 30, established CV disease, or documented intolerance)
• Not concurrent with other GLP-1 receptor agonists or insulin as specified

PA criteria for Zepbound (NDA 217806) typically require:

• Confirmed BMI ≥ 30 kg/m², or BMI ≥ 27 kg/m² with at least one qualifying weight-related comorbid condition (hypertension, dyslipidemia, obstructive sleep apnea, T2DM, or cardiovascular disease — varies by plan)
• Documented behavioral modification attempt (3 months in some plans, 6 months in others)
• BMI re-documented within the past 12 months
• Not currently on another GLP-1 or tirzepatide product

A patient with T2DM who meets both sets of criteria may theoretically receive either brand under the appropriate PA pathway. In practice, prescribers write the brand that matches the patient's primary insurance coverage tier. A patient without T2DM cannot satisfy the Mounjaro criteria. A patient without BMI meeting the Zepbound threshold (and without the qualifying OSA pathway) cannot satisfy Zepbound criteria either.

Pricing differences: savings programs and list price

Eli Lilly has taken different commercial strategies for each brand's patient access programs. As of 2026, the material pricing difference is:

Zepbound: manufacturer-run self-pay program

Lilly launched the LillyDirect Self Pay Journey Program for Zepbound vials in December 2025. This program allows cash-pay patients to purchase Zepbound tirzepatide vials directly at manufacturer-set prices without going through insurance. The vial format contains four doses in a multi-dose vial. The program requires a valid prescription and is only available to patients without insurance coverage for Zepbound, or who choose to pay out of pocket.

Zepbound is also available through LillyDirect and Sam's Club in single-patient-use KwikPen format at prices that vary by strength. A manufacturer-funded GoodRx discount for the Zepbound KwikPen has also been active as of 2026. Amazon Pharmacy has been a distribution channel for the LillyDirect program.

Mounjaro: no equivalent self-pay program

Mounjaro does not have a comparable manufacturer-run DTC self-pay program for cash-pay patients without insurance coverage. The Mounjaro Savings Card is a copay assistance program for commercially insured patients who have a valid prescription with insurance coverage — it is not a cash-pay alternative. Patients without commercial insurance who need Mounjaro for T2DM typically access it through their insurance benefit or through manufacturer patient-assistance programs.

Savings card eligibility difference

Both brands offer savings cards, but the eligibility criteria reflect the indication difference:

• Mounjaro Savings Card: available to commercially insured patients with a Mounjaro prescription for T2DM. Medicare, Medicaid, and government-plan patients are typically excluded.
• Zepbound Savings Card: available to commercially insured patients with a Zepbound prescription for chronic weight management or OSA. Medicare, Medicaid, and government-plan patients are typically excluded.

A patient with commercial insurance who is prescribed Mounjaro off-label for weight loss (not for T2DM) may find that the Mounjaro Savings Card is not applicable if the prescription lacks the T2DM indication, and may also find that the insurance plan denies coverage for the off-label use. In that scenario, the patient faces the full list price with no manufacturer discount. This is one of the concrete financial reasons why prescribers typically write Zepbound rather than Mounjaro when the patient's goal is weight management.

The off-label Mounjaro for weight loss situation

One of the most common questions about Mounjaro and Zepbound comes from patients who are on Mounjaro for weight loss and encounter insurance problems. The situation unfolds like this:

1. A prescriber writes Mounjaro for a patient who does not have T2DM (or does have T2DM but whose primary goal is weight management). Off-label prescribing is legal and within the prescriber's discretion.
2. The insurance plan processes the PA request for Mounjaro. The PA system checks for the T2DM diagnosis. If the patient's chart does not document T2DM (or if the plan's T2DM criteria are not met), the PA is denied.
3. The patient receives an explanation of benefits stating that Mounjaro is not covered for the prescribed indication. This is not a mistake — it is the insurance plan applying its criteria correctly per NDA 215866's approved indication.

What patients in this situation can do:

• Ask the prescriber to write Zepbound instead. If the patient meets the Zepbound obesity BMI threshold, the prescriber can write Zepbound under the NDA 217806 coverage pathway. The molecule is identical; the patient's clinical experience will be the same.
• Request a prior authorization for Zepbound under the obesity indication. This requires documenting BMI and any qualifying comorbidities. Some patients with T2DM and obesity qualify for both Mounjaro and Zepbound under separate PA criteria.
• Appeal the Mounjaro denial. In some cases, a patient with pre-diabetes, insulin resistance, or documented metabolic syndrome may be able to construct a medically necessary argument under the plan's internal appeal process. This is plan-specific and has a lower success rate than a correct initial PA under the intended brand.
• Use Zepbound's LillyDirect self-pay program if the patient is cash-pay eligible. The self-pay vials program does not apply to Mounjaro, so there is no equivalent cash-pay discount on Mounjaro for out-of-pocket weight management use.

For the full playbook on what to do when insurance drops GLP-1 coverage — including the appeal letter framework, the PA re-application path, and the formulary-exception process — see our GLP-1 insurance coverage appeal playbook.

Switching between Mounjaro and Zepbound

Because the active ingredient, dose strengths, injection schedule, and titration schedule are identical, switching between Mounjaro and Zepbound is pharmacologically trivial. The only barrier is administrative.

The switch typically happens in one direction: Mounjaro to Zepbound. The most common scenarios driving this switch:

• Insurance indication realignment. A patient initially prescribed Mounjaro under T2DM coverage achieves glycemic targets and now wants continued prescribing under the weight management indication. The prescriber switches the brand to Zepbound, submits a new PA under the obesity indication, and the patient continues the same dose.
• Loss of T2DM diagnosis after weight loss. Tirzepatide can produce glycemic remission in patients with T2DM. Some patients who achieve remission (HbA1c below 6.5% without antidiabetic medication) may no longer qualify for Mounjaro under the T2DM PA criteria. Switching to Zepbound under the obesity indication maintains coverage.
• Formulary change. If a plan adds Zepbound to a preferred tier while Mounjaro moves to a non-preferred tier (or is removed), the prescriber may switch brands for cost reasons.
• Access to self-pay vials. A patient who moves to a self-pay model wants to use the LillyDirect Self Pay Journey Program, which is only available for Zepbound.

The switch does not require a washout period, a dose reduction, or any clinical transition. The prescriber writes a new Zepbound prescription at the same dose strength as the patient's current Mounjaro dose. No re-titration from 2.5 mg is required because the molecule and effect are the same. Confirm this with your prescriber.

Side effects and warnings: identical

Section 5 (Warnings and Precautions) shares identical core content across both labels because the molecule driving the risks is the same.

Boxed warning: risk of thyroid C-cell tumors

The Mounjaro boxed warning states verbatim:

“In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.”Mounjaro PI Boxed Warning, DailyMed SetID d2d7da5d, revised 4/2026

The Zepbound boxed warning states verbatim:

“In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.”Zepbound PI Boxed Warning, DailyMed SetID 487cd7e7, revised 4/2026

Both brands are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Most common adverse reactions

The Mounjaro label (Section 6, revised 4/2026) states:

“The most common adverse reactions, reported in ≥5% of patients treated with MOUNJARO are nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain.”Mounjaro PI Section 6, DailyMed SetID d2d7da5d, revised 4/2026

The Zepbound label (Section 6, revised 4/2026) states:

“The most common adverse reactions, reported in ≥5% of patients treated with ZEPBOUND are: nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, gastroesophageal reflux disease.”Zepbound PI Section 6, DailyMed SetID 487cd7e7, revised 4/2026

The Zepbound list is longer because the SURMOUNT trials enrolled patients without T2DM at higher doses and for longer durations, which generated a larger adverse-event data set for the label. Both profiles are dominated by gastrointestinal effects that are characteristic of GLP-1 receptor agonists as a class: nausea, diarrhea, vomiting, constipation. For deeper GLP-1 side-effect context, see our GLP-1 side effects: questions answered.

Additional warnings present in both labels (Section 5) include: acute pancreatitis, hypoglycemia risk with concomitant insulin secretagogues or insulin, hypersensitivity reactions (including anaphylaxis and angioedema), acute kidney injury due to volume depletion from GI adverse reactions, severe gastrointestinal adverse reactions, and pulmonary aspiration risk during general anesthesia or deep sedation (the anesthesia fasting warning). These warnings apply equally to both brands because they reflect the pharmacology of tirzepatide, not the indication.

Clinical trials: SURPASS vs SURMOUNT

Eli Lilly ran two separate phase 3 trial programs for tirzepatide, one for each indication. The trial program name (SURPASS vs SURMOUNT) corresponds directly to the brand name (Mounjaro vs Zepbound). Because the molecule is identical, both programs generated weight-loss data even though only SURMOUNT was designed to study weight loss as the primary outcome.

SURPASS program: tirzepatide in T2DM (Mounjaro data)

SURPASS-1 (Rosenstock 2021, Lancet, PMID 34186022) was a 40-week, double-blind, placebo-controlled, phase 3 trial of tirzepatide as monotherapy in 478 adults with T2DM. Participants were randomized to tirzepatide 5, 10, or 15 mg once weekly or placebo. The primary endpoint was change in HbA1c from baseline:

• Tirzepatide 5 mg: HbA1c −1.87%
• Tirzepatide 10 mg: HbA1c −1.89%
• Tirzepatide 15 mg: HbA1c −2.07%
• Placebo: HbA1c −0.04%

Body-weight reductions were a secondary outcome. All three doses produced statistically significant weight reductions in a T2DM population, confirming that tirzepatide's weight-loss effect is not restricted to non-diabetic patients.

SURPASS-2 (Frías 2021, NEJM, PMID 34170647) compared tirzepatide directly against semaglutide 1 mg (the T2DM dose of Ozempic) in 1879 adults with T2DM over 40 weeks. All three tirzepatide doses (5, 10, 15 mg) achieved statistically superior HbA1c reductions compared with semaglutide 1 mg. Tirzepatide 15 mg produced a mean 5.5 kg greater body-weight reduction than semaglutide 1 mg in this T2DM population.

SURMOUNT program: tirzepatide in obesity (Zepbound data)

SURMOUNT-1 (Jastreboff 2022, NEJM, PMID 35658024) was a 72-week, double-blind, placebo-controlled, phase 3 trial of tirzepatide in 2539 adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m² with at least one weight-related comorbidity) but without T2DM. Participants were randomized to tirzepatide 5, 10, or 15 mg once weekly or placebo, plus lifestyle intervention. At 72 weeks:

• Tirzepatide 5 mg: −15.0% mean body-weight reduction
• Tirzepatide 10 mg: −19.5% mean body-weight reduction
• Tirzepatide 15 mg: −20.9% mean body-weight reduction
• Placebo: −3.1% mean body-weight reduction

SURMOUNT-1 is the primary efficacy data supporting the Zepbound FDA approval for chronic weight management. At the 15 mg dose, 91% of participants achieved ≥5% weight loss, 57% achieved ≥20% weight loss.

SURMOUNT-2 (Garvey 2023, Lancet, PMID 37385275) studied tirzepatide specifically in adults with both obesity and type 2 diabetes — the patient population that overlaps Mounjaro and Zepbound indications. The trial enrolled 938 adults with T2DM and obesity; tirzepatide 10 and 15 mg were compared to placebo over 72 weeks. Mean body-weight reductions at 72 weeks:

• Tirzepatide 10 mg: −13.4%
• Tirzepatide 15 mg: −15.7%
• Placebo: −3.3%

SURMOUNT-2 demonstrated that tirzepatide produces substantial weight loss in patients with T2DM — the same population who might receive Mounjaro for glycemic control and experience significant weight reduction as a secondary benefit. The SURMOUNT-2 data supported the expanded Zepbound label language covering adults with obesity and type 2 diabetes.

Taken together: the SURPASS program proved tirzepatide is effective for T2DM. The SURMOUNT program proved tirzepatide is effective for weight management. Both programs showed weight loss because tirzepatide produces weight loss regardless of the patient's diabetes status — confirming that the biological effect crosses both indications. The regulatory differentiation into two brands reflects FDA indication architecture, not biological differentiation.

What to ask your prescriber

If you have questions about Mounjaro versus Zepbound, the most productive conversation with your prescriber covers these five questions:

1. “Which indication does my insurance cover for tirzepatide?” This determines whether Mounjaro or Zepbound is the correct NDA for your plan's PA pathway. If you have both T2DM and obesity, ask which coverage path is stronger.
2. “If I need to switch brands, will I maintain my current dose?” Because the molecule and doses are identical, most prescribers maintain the current dose strength when switching. Confirm this expectation before filling a new prescription.
3. “Do I qualify for any manufacturer savings programs?”Eligibility for the Mounjaro Savings Card and the Zepbound Savings Card depends on your insurance type and the written indication. If you are cash-pay, ask specifically about the Zepbound LillyDirect Self Pay Journey Program.
4. “Is there any clinical reason to prefer one brand over the other in my specific case?” For most patients, the answer is no — the biology is the same. The prescriber's recommendation should be driven by your insurance coverage path. If you have a specific formulation preference (vial vs pen, for example), mention it.
5. “What is the PA re-application plan if my current brand loses coverage?” Formulary changes happen. Ask your prescriber whether your documentation supports the alternative brand's PA criteria as a fallback.